In our study, 8 of 397 TP53, BRCA1 and BRCA2 PV carriers (2%) had a synchronous breast cancer diagnosis compared to 0 synchronous cancers in 261 non-carriers, reflecting the increased risk of a secondary cancer within 3 months in association with inherited tumor syndromes. This evidence concerns the gene BRCA1 and neoplastic syndrome.